A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Draghiciu, Oana ^a   Boerma, Annemarie ^a   Hoogeboom, Baukje Nynke ^a   Nijman, Hans W ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cancer vaccine; low dose local tumor irradiation; Semliki Forest virus; sunitinib; suppressive factors

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; CD69 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; STAT3 PROTEIN; SUNITINIB; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BHK CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; SEMLIKI FOREST VIRUS; SUPPRESSOR CELL; T CELL DEPLETION; VACCINATION;

EID: 84940705588     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1029699     Document Type: Article

References (42)

1. T.L.Whiteside. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16:3-15; PMID:16153857; http://dx.doi.org/10.1016/j.semcancer.2005.07.008.
2. A.A.Van der Veldt, M.Lubberink, I.Bahce, M.Walraven, M.P.de Boer, H.N.Greuter, N.H.Hendrikse, J.Eriksson, A.D.Windhorst, P.E.Postmus, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: Implications for scheduling of anti-angiogenic drugs. Cancer Cell 2012; 21:82-91; PMID:22264790; http://dx.doi.org/10.1016/j.ccr.2011.11.023.
3. O.Draghiciu, H.W.Nijman, T.Daemen. From tumor immunosuppression to eradication: Targeting homing and activity of immune effector cells to tumors. Clin Dev Immunol 2011; 2011:439053; PMID:22190971; http://dx.doi.org/10.1155/2011/439053.
4. O.Draghiciu, M.Walczak, B.N.Hoogeboom, K.L.Franken, K.J.Melief, H.W.Nijman, T.Daemen. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int J Cancer 2014; 134:859-72; PMID:23922012; http://dx.doi.org/10.1002/ijc.28418.
5. B.J.Moeller, Y.Cao, C.Y.Li, M.W.Dewhirst. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5:429-41; PMID:15144951.
6. M.Chiriva-Internati, F.Grizzi, J.Pinkston, K.J.Morrow, N.D'Cunha, E.E.Frezza, P.C.Muzzio, W.M.Kast, E.Cobos. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim 2006; 42:89-95; PMID:16759154; http://dx.doi.org/10.1290/0508054.1.
7. S.A.Amundson, M.B.Grace, C.B.McLeland, M.W.Epperly, A.Yeager, Q.Zhan, J.S.Greenberger, A.J.FornaceJr. Human in vivo radiation-induced biomarkers: Gene expression changes in radiotherapy patients. Cancer Res 2004; 64:6368-71; PMID:15374940; http://dx.doi.org/10.1158/0008-5472.CAN-04-1883.
8. S.Matsumura, B.Wang, N.Kawashima, S.Braunstein, M.Badura, T.O.Cameron, J.S.Babb, R.J.Schneider, S.C.Formenti, M.L.Dustin, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980.
9. R.Ganss, E.Ryschich, E.Klar, B.Arnold, G.J.Hammerling. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62:1462-70; PMID:11888921.
10. A.Sica, V.Bronte. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117:1155-66; PMID:17476345; http://dx.doi.org/10.1172/JCI31422.
11. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506.
12. A.M.Molina, R.J.Motzer, D.Y.Heng. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol 2013; 40:436-43; PMID:23972707; http://dx.doi.org/10.1053/j.seminoncol.2013.05.013.
13. R.J.Motzer, B.I.Rini, R.M.Bukowski, B.D.Curti, D.J.George, G.R.Hudes, B.G.Redman, K.A.Margolin, J.R.Merchan, G.Wilding, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-24; PMID:16757724; http://dx.doi.org/10.1001/jama.295.21.2516.
14. H.Xin, C.Zhang, A.Herrmann, Y.Du, R.Figlin, H.Yu. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323.
15. V.F.Bampi, C.F.Gomes, L.B.De Oliveira, J.L.Da Silva. The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma. Microsc Res Tech 2014; 77:250-6; PMID:24458724; http://dx.doi.org/10.1002/jemt.22336.
16. S.de Bouard, P.Herlin, J.G.Christensen, E.Lemoisson, P.Gauduchon, E.Raymond, J.S.Guillamo. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007; 9:412-23; PMID:17622648; http://dx.doi.org/10.1215/15228517-2007-024.
17. J.S.Ko, P.Rayman, J.Ireland, S.Swaidani, G.Li, K.D.Bunting, B.Rini, J.H.Finke, P.A.Cohen. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi.org/10.1158/0008-5472.CAN-09-3278.
18. C.Iclozan, S.Antonia, A.Chiappori, D.T.Chen, D.Gabrilovich. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62:909-18; PMID:23589106; http://dx.doi.org/10.1007/s00262-013-1396-8.
19. M.K.Srivastava, L.Zhu, M.Harris-White, U.K.Kar, M.Huang, M.F.Johnson, J.M.Lee, D.Elashoff, R.Strieter, S.Dubinett, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS One 2012; 7:e40677; PMID:22815789; http://dx.doi.org/10.1371/journal.pone.0040677.
20. T.Daemen, A.Riezebos-Brilman, J.Regts, B.Dontje, A.van der Zee, J.Wilschut. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: Effects of the route of immunization. Antivir Ther 2004; 9:733-42; PMID:15535411.
21. A.de Mare, A.J.Lambeck, J.Regts, G.M.van Dam, H.W.Nijman, H.Snippe, J.Wilschut, T.Daemen. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition. Gene Ther. 2008 Mar;15(6):393-403.
22. A.Riezebos-Brilman, M.Walczak, J.Regts, M.G.Rots, G.Kamps, B.Dontje, H.Y.Haisma, J.Wilschut, T.Daemen. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther. 2007 Dec;14(24):1695-704.
23. D.OanaDraghiciu, W.Hans. Nijman, Baukje Nynke Hoogeboom, Tjarko Meijerhof, Toos Daemen. Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology 2015; 4(3):e989764; http://dx.doi.org/10.4161/2162402X.2014.989764.
24. W.B.Lindsey, M.W.Lowdell, G.E.Marti, F.Abbasi, V.Zenger, K.M.King, L.S.LambJr. CD69 expression as an index of T-cell function: Assay standardization, validation and use in monitoring immune recovery. Cytotherapy 2007; 9:123-32; PMID:17453964; http://dx.doi.org/10.1080/14653240601182838.
25. M.R.Betts, J.M.Brenchley, D.A.Price, S.C.De Rosa, D.C.Douek, M.Roederer, R.A.Koup. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78; PMID:14580882.
26. A.Hoos, C.M.Britten, C.Huber, J.O'Donnell-Tormey. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol 2011; 29:867-70; PMID:21997622; http://dx.doi.org/10.1038/nbt.2000.
27. S.Kusmartsev, F.Cheng, B.Yu, Y.Nefedova, E.Sotomayor, R.Lush, D.Gabrilovich. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003; 63:4441-9; PMID:12907617.
28. C.De Santo, P.Serafini, I.Marigo, L.Dolcetti, M.Bolla, P.Del Soldato, C.Melani, C.Guiducci, M.P.Colombo, M.Iezzi, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A 2005; 102:4185-90; PMID:15753302; http://dx.doi.org/0409783102 [pii].
29. S.Nagaraj, J.I.Youn, H.Weber, C.Iclozan, L.Lu, M.J.Cotter, C.Meyer, C.R.Becerra, M.Fishman, S.Antonia, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010; 16:1812-23; PMID:20215551; http://dx.doi.org/10.1158/1078-0432.CCR-09-3272.
30. J.Ozao-Choy, G.Ma, J.Kao, G.X.Wang, M.Meseck, M.Sung, M.Schwartz, C.M.Divino, P.Y.Pan, S.H.Chen. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69:2514-22; PMID:19276342; http://dx.doi.org/10.1158/0008-5472.CAN-08-4709.
31. J.Finke, J.Ko, B.Rini, P.Rayman, J.Ireland, P.Cohen. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11:856-61; PMID:21315783; http://dx.doi.org/10.1016/j.intimp.2011.01.030.
32. H.Xin, C.Zhang, A.Herrmann, Y.Du, R.Figlin, H.Yu. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323.
33. M.Walczak, J.Regts, A.J.van Oosterhout, L.Boon, J.Wilschut, H.W.Nijman, T.Daemen. Role of regulatory T-cells in immunization strategies involving a recombinant alphavirus vector system. Antivir Ther 2011; 16:207-18; PMID:21447870; http://dx.doi.org/10.3851/IMP1751.
34. S.Shukla, S.Mahata, G.Shishodia, A.Pandey, A.Tyagi, K.Vishnoi, S.F.Basir, B.C.Das, A.C.Bharti. Functional regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis. PLoS One. 2013 Jul 18;8(7):e67849.
35. C.Ren, X.Cheng, B.Lu, G.Yang. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer. 2013 Dec;49(18):3889-99; http://dx.doi.org/10.1016/j.ejca.2013.07.140.
36. A.Bose, J.L.Taylor, S.Alber, S.C.Watkins, J.A.Garcia, B.I.Rini, J.S.Ko, P.A.Cohen, J.H.Finke, W.J.Storkus. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011; 129:2158-70; PMID:21170961; http://dx.doi.org/10.1002/ijc.25863.
37. A.Bose, D.B.Lowe, A.Rao, W.J.Storkus. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 2012; 22:236-43; PMID:22504156; http://dx.doi.org/10.1097/CMR.0b013e3283538293.
38. R.Jaini, P.Rayman, P.A.Cohen, J.H.Finke, V.K.Tuohy. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int J Cancer 2014; 134:1695-705; PMID:24105638; http://dx.doi.org/10.1002/ijc.28488.
39. H.Sheng Sow, S.R.Mattarollo. Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas. Oncoimmunology 2013; 2:e27058; PMID:24498564; http://dx.doi.org/10.4161/onci.27058.
40. E.M.Weiss, R.Wunderlich, N.Ebel, Y.Rubner, E.Schlucker, R.Meyer-Pittroff, O.J.Ott, R.Fietkau, U.S.Gaipl, B.Frey. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol 2012; 2:132; PMID:23087898; http://dx.doi.org/10.3389/fonc.2012.00132.
41. K.Y.Lin, F.G.Guarnieri, K.F.Staveley-O'Carroll, H.I.Levitsky, J.T.August, D.M.Pardoll, T.C.Wu. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56(1):21-6.
42. A.J.Lambeck, H.W.Nijman, B.N.Hoogeboom, J.Regts, A.de Mare, J.Wilschut, T.Daemen. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens. Vaccine 2010; 28:4275-82; PMID:20434555; http://dx.doi.org/10.1016/j.vaccine.2010.04.033.